Scientific Letters
Vol. 18 No. 1 (2026): Mediterranean Journal of Hematology and Infectious Diseases
Fatal disseminated fusariosis during induction therapy for adult acute lymphoblastic leukemia in a patient with prior multiple myeloma
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: September 1, 2026
0
Views
0
Downloads
Authors
Invasive fungal infections are a major cause of morbidity and mortality in patients with hematologic malignancies, particularly during prolonged neutropenia and intensive chemotherapy. In acute lymphoblastic leukemia (ALL), prophylaxis is challenging because mold-active azoles interact with vinca alkaloids and may increase hepatotoxicity with asparaginase, whereas provide incomplete coverage against Aspergillus spp. and rare molds such as Fusarium spp. We report a fatal case of proven cutaneous invasive fusariosis with radiologically presumed pulmonary dissemination during induction therapy for Philadelphia-negative B-cell precursor ALL (BCP-ALL) in a 58-year-old man with heavily pretreated multiple myeloma (MM).
Downloads
Download data is not yet available.
Citations
1. Bassan R, Chiaretti S, Della Starza I, Spinelli O, Santoro A, Paoloni F, et al. Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial. Blood Adv. 2023 Jun 7;7(16):4448–61.
2. Lussana F, Minetto P, Ferrara F, Chiaretti S, Specchia G, Bassan R. National Italian Delphi panel consensus: which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia? BMC Cancer. 2020 Oct 2;20(1):956.
3. Bupha-Intr O, Butters C, Reynolds G, Kennedy K, Meyer W, Patil S, et al. Consensus guidelines for the diagnosis and management of invasive fungal disease due to moulds other than Aspergillus in the haematology/oncology setting, 2021. Intern Med J. 2021 Nov;51 Suppl 7:177–219.
4. Hoenigl M, Salmanton-García J, Walsh TJ, Nucci M, Neoh CF, Jenks JD, et al. Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. Lancet Infect Dis. 2021 Aug;21(8):e246–57.
5. Kriegl L, Egger M, Boyer J, Hoenigl M, Krause R. New treatment options for critically important WHO fungal priority pathogens. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2025 Jun;31(6):922–30.
6. Pagano L, Maschmeyer G, Lamoth F, Blennow O, Xhaard A, Spadea M, et al. Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL). Leukemia. 2025 Apr 9.
7. Stemler J, Mellinghoff SC, Khodamoradi Y, Sprute R, Classen AY, Zapke SE, et al. Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). J Antimicrob Chemother. 2023 Aug 2;78(8):1813–26.
8. Stafylidis C, Diamantopoulos P, Athanasoula E, Solomou E, Anastasopoulou A. Acute Lymphoblastic Leukemia and Invasive Mold Infections: A Challenging Field. J Fungi Basel Switz. 2022 Oct 26;8(11):1127.
9. Maertens J, Pagano L, Azoulay E, Warris A. Liposomal amphotericin B—the present. J Antimicrob Chemother. 2022 Nov 25;77(Suppl 2):ii11–20.
10. Nucci M, Barreiros G, Akiti T, Anaissie E, Nouér SA. Invasive Fusariosis in Patients with Hematologic Diseases. J Fungi Basel Switz. 2021 Sep 28;7(10):815.
11. Nucci M, Anaissie E. Invasive fusariosis. Clin Microbiol Rev. 2023 Dec 20;36(4):e0015922.
12. Nucci M, Anaissie EJ, Queiroz-Telles F, Martins CA, Trabasso P, Solza C, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer. 2003 Jul 15;98(2):315–9.
13. Blimark CH, Carlson K, Day C, Einarsdottir S, Juliusson G, Karma M, et al. Risk of infections in multiple myeloma. A population-based study on 8,672 multiple myeloma patients diagnosed 2008-2021 from the Swedish Myeloma Registry. Haematologica. 2024 Jul 18;110(1):163–72.
14. Encinas C, Blanchard MJ, Fernández RA, Hernández-Rivas JÁ, Tamayo RR, Machado-Vílchez M, et al. Factors Increasing the Risk of Infection in Patients With Multiple Myeloma: From Biology to Prevention. Clin Lymphoma Myeloma Leuk. 2025 Jun;S2152265025002204.
15. Weerasinghe H, Stölting H, Rose AJ, Traven A. Metabolic homeostasis in fungal infections from the perspective of pathogens, immune cells, and whole-body systems. Heitman J, editor. Microbiol Mol Biol Rev. 2024 Sep 26;88(3):e00171-22.
16. Nucci M, Nouér SA. Practical issues related to non-Aspergillus invasive mold infections. Mol Aspects Med. 2023 Dec;94:101230.
17. Muscogiuri G, Pugliese G, Laudisio D, Castellucci B, Barrea L, Savastano S, et al. The impact of obesity on immune response to infection: Plausible mechanisms and outcomes. Obes Rev. 2021;22(6):e13216.
18. Cornely OA, Leguay T, Maertens J, Vehreschild MJGT, Anagnostopoulos A, Castagnola C, et al. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. J Antimicrob Chemother. 2017 Aug 1;72(8):2359–67.
19. Poh C, Keegan T, Rosenberg AS. Second primary malignancies in multiple myeloma: A review. Blood Rev. 2021 Mar;46:100757.
20. Barnell EK, Skidmore ZL, Newcomer KF, Chavez M, Campbell KM, Cotto KC, et al. Distinct clonal identities of B-ALLs arising after lenalidomide therapy for multiple myeloma. Blood Adv. 2023 Jan 24;7(2):236–45.
Ethics Approval
acute lymphoblastic leukemia, Multiple Myeloma, Fusariosis, fungal infectionsSupporting Agencies
NoneHow to Cite
“Fatal disseminated fusariosis during induction therapy for adult acute lymphoblastic leukemia in a patient with prior multiple myeloma” (2026) Mediterranean Journal of Hematology and Infectious Diseases, 18(1), p. e2026074. doi:10.4084/MJHID.2026.074.
Copyright (c) 2026 Sara Alberti, Gianluca Cavallaro, Alessandra Tebaldi, Paola Tebaldi, Maria Chiara Finazzi, Anna Grassi, Monica Galli, Laura Paris, Paola Stefanoni, Francesca Valsecchi, Alessandro Rambaldi, Federico Lussana
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
